TTPH Tetraphase Pharmaceuticals Inc.

0.65
0  0%
Previous Close 0.65
Open
Price To Book 0.56
Market Cap 35,407,131
Shares 54,263,802
Volume 10
Short Ratio
Av. Daily Volume 533,365

NewsSee all news

  1. Edited Transcript of TTPH earnings conference call or presentation 8-May-19 8:30pm GMT
  2. Robbins Arroyo LLP: Tetraphase Pharmaceuticals, Inc. (TTPH) Accused of Misleading Shareholders
  3. What You Should Know About Tetraphase Pharmaceuticals, Inc.'s (NASDAQ:TTPH) Financial Strength
  4. The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes
  5. Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA™ (Eravacycline) Commercial Opportunity

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial also did not meet primary endpoints - noted February 13, 2018.
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
FDA approval announced August 27, 2018.
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)
Phase 1 trial complete.
TP-271
Community-acquired bacterial pneumonia (CABP)
Phase 1 bronchopulmonary disposition trial to be completed 2H 2019.
TP-6076

Latest News

  1. Edited Transcript of TTPH earnings conference call or presentation 8-May-19 8:30pm GMT
  2. Robbins Arroyo LLP: Tetraphase Pharmaceuticals, Inc. (TTPH) Accused of Misleading Shareholders
  3. What You Should Know About Tetraphase Pharmaceuticals, Inc.'s (NASDAQ:TTPH) Financial Strength
  4. The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes
  5. Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA™ (Eravacycline) Commercial Opportunity
  6. Tetraphase Pharmaceuticals Announces New XERAVA™ (eravacycline) Data at the 39th Annual Surgical Infection Society Meeting
  7. Tetraphase Pharmaceuticals to Present Data at the 39th Annual Meeting of the Surgical Infection Society
  8. Tetraphase Pharmaceuticals Inc (TTPH) Q1 2019 Earnings Call Transcript
  9. Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Misses Revenue Estimates
  10. Tetraphase: 1Q Earnings Snapshot
  11. Tetraphase Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Corporate Developments
  12. Edited Transcript of TTPH earnings conference call or presentation 14-Mar-19 8:30pm GMT
  13. Tetraphase Pharmaceuticals to Present Data at the 22nd Annual MAD-ID Meeting
  14. Tetraphase Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call
  15. Tetraphase Pharmaceuticals to Participate in Upcoming Investor Conferences
  16. Easy Come, Easy Go: How Tetraphase Pharmaceuticals (NASDAQ:TTPH) Shareholders Got Unlucky And Saw 90% Of Their Cash Evaporate
  17. Will Tetraphase Pharmaceuticals (TTPH) Report Negative Q1 Earnings? What You Should Know
  18. Tetraphase Pharmaceuticals to Present Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
  19. Tetraphase Pharmaceuticals Presents Preclinical Data on TP-2846, a Novel Drug Candidate for Acute Myeloid Leukemia